EGFR and cancer: In particular, EGF and another ERBB ligand, Heregulin1 (HRG1), could protect cancer cells from action of lapatinib (Claus et al., 2018; Kamashev et al., 2021; Wang et al., 2016; Wilson et al., 2012; Canadas et al., 2014; Sato et al., 2013).